Red Blood Cell replacement or nanobiotherapeutics with enhanced red blood cell functions?

Professor TMS Chang, OC, MD, CM, PhD, FRCPC, FRSC,
Director, Artificial Cells and Organs Research Centre, Depts Physiology, Medicine & Biomedical Engineering,
Faculty of Medicine, McGill University. www.medicine.mcgill.ca/artcell

Published later in Journal Artificial Cells, Nanomedicine and Biotechnology 43, 3, 145-147, 2015

Abstract
Why is this important?
Under normal circumstances, donor blood is the best replacement for blood. HOWEVER:

- Natural epidemics (e.g. HIV, Ebola etc) or man-made epidemics (terrorism, war, etc) can result in contaminated donor blood or disqualified disease contact donors. (unlike rbc, blood substitutes can be sterilized to remove infective agents)
- Heart attack and stroke are usually caused by obstruction of arterial blood vessels. Unlike rbc particles, blood substitute is a solution and in animal studies it can more easily perfuse through obstructed vessels to reach the heart and brain.
- Severe blood loss from accidents, disasters or war may require urgent blood transfusion that cannot wait for transportation to the hospital for blood group testing. (unlike red blood cells (rbc), blood substitutes do not have blood groups and can be given on the spot)
- Red blood cells have to be stored in refrigeration for up to 42 days thus difficult to transport and store in disaster and frontline. (Blood substitutes can be stored at room temperature for more than 1 year, compared to rbc of 1 day at room temperature)
- In very severe hemorrhagic shock there is usually a safety window of 60 min for blood replacement, beyond which there could be problems related to irreversible shock. Animal study shows that one type of blood substitutes with enhanced rbc enzymes may be able to prolong the time..

What is the present status around the world?
The first report of artificial cells includes artificial red blood cells (Chang, Science, 1964, Chang & Poznansky, Nature, 1968, Chang, Nature 1971a) (with support from MRC Canada). Most people thought that blood substitute was a simple matter that could be quickly developed when needed. Thus blood substitute research was put aside and only the other areas of artificial cells were extensively developed around the world for wide spread uses (e.g. Chang Nature Rev Drug Disc 2005, Orive et al Nature Medicine 2003, Chang, 2007). When AIDS came in 1989 there was no blood substitutes and many patients were infected with H.I.V. contaminated donor blood. It was only then that intense R&D on blood substitutes was belatedly carried out around the world. It was found out too late that blood substitute requires the same long-term research as in any other medical research for cancer and other diseases. Thus, the present status is only as follows (Przybelski et al 1996, Tsuchida 1998, Klein 2000, Kobayashi et al 2005, Winslow 2006, Zuck 2006, Liu & Xiu 2008, Mozzarelli & Bettati 2011, Zapol 2011, Yang, Liu, Zheng 2013, Chang 2013, Kim & Greenburg 2014, Weiskopf 2014):

Red blood cells have 3 major functions: (1) transport oxygen from the lung to the tissue, (2) remove damaging oxygen radicals and (3) carry carbon dioxide CO2. from the tissue to the lung to be removed.

(1) Oxygen carriers (HBOCs): It is thus not surprising that after more than 20 years of R&D around the world only oxygen carriers have been tested clinically. The most extensive clinical trials were based on polyhemoglobin (PolyHb) developed independently mainly by two groups (Northfield on human PolyHb and Biopure on bovine PolyHb) using the basic principle of glutaraldehyde crosslinked hemoglobin first reported by Chang (1971b). This has no blood groups and can be pasteurized to remove infective agents and can be stored at room temperature for more than 1 year. Large-scale clinical trials have been carried out (e.g. Gould et al, 2002, Jahr et al 2008) including using this in the ambulance without the need for typing or cross matching (Moore et al 2009). Oxygen carriers are commonly called “oxygen therapeutics”. For some conditions, in addition to oxygen, there may also be a need for the other 2 red blood cell (rbc) functions: remove harmful oxygen radicals and transport CO2.

(3) **All 3 rbc functions (Carries Oxygen + removes oxygen radicals + carries carbon dioxide)**. Other conditions as in sustained severe hemorrhagic shock may require all three rbc functions. With support from the CIHR/Canadian Blood Service, we have designed a novel soluble nanobiotechnological complex (PolyHb-SOD-CAT-CA). It not only has all 3 rbc functions, but it can have enhancement of all 3 rbc functions by increasing the concentrations of rbc enzymes in the complex. These rbc enzymes can be extracted from rbc inexpensively (Guo, Gynn & Chang 2015). This complex has no blood groups. The lyophilized preparation can be heat pasteurized at 68F for 2 h. This can be important if there is a need to inactivate H.I.V. virus, Ebola virus, and other infective organisms. Unlike about 1 day for rbc at room temperature, this lyophilized preparation can be stored in room temperature for 320 days. Our result in a 90 minutes hemorrhagic shock animal model with 2/3 blood volume loss shows that it is superior to whole blood in the following ways: lowering of elevated intracellular pCO2, recovery of ST elevation, protonin levels, lowering of elevated lactate, histology of the heart and intestine. More details in Bian & Chang JANB 2014 early online full text freely available at [http://informahealthcare.com/doi/pdf/10.3109/21691401.2014.964554](http://informahealthcare.com/doi/pdf/10.3109/21691401.2014.964554).

International progress up to now shows that it is possible to tailor-make blood substitutes ranging from simple to complex. It is urgent to have these ready without again waiting until it is too late. We need to analyze the specific indications for 1,2 and 3 above. If a condition only needs oxygen then there is no need to use a more complex one. On the other hand, it would be folly not to use a more complex one if indicated. We also need to intensify research on the many important ongoing research around the world (references for these are in the next page). Examples include: develop other novel approaches including novel crosslinkers; new sources of material from porcine, bovine, human cord rbc, recombinant, Arenicola marina; basic research on nitric oxide, oxidative stress, haptoglobin, rate of oxygen supply; safety and efficacy analysis and many other areas. The 2015 XV Int Symposium on Blood Substitute at Lund University (Professor Lief Bulow), Lund, Sweden [http://isbs2015.lu.se](http://isbs2015.lu.se) to be followed by the 2017 XVI at McGill University (Professor TMS Chang), Montreal Canada [www.medicine.mcgill.ca/artcell](http://www.medicine.mcgill.ca/artcell), will be excellent opportunities for international exchanges.

**Acknowledgements**

This area of research at the author’s laboratory is at present being supported by an operating grant of the Canada Blood Service/Canadian Institutes of Health Research that require the author to state that the opinions in this paper are those of the author and not necessary of the granting agencies or the government of Canada. The author has no connection to commercial organization.

**References**


Greenburg AG (2013) in “Selected Topics in Nanomedicine” Editor TMS Chang, World Science Publisher/Imperial College Press
Jia,YP and Alayash Al (2013). in “Selected Topics in Nanomedicine” Editor TMS Chang, World Science Publisher/Imperial College Press
Kim, HW and AG Greenburg. (2014) Book on HBOC and OxygenTherapeutics. Springer Publisher.
Ma, L and Hsia CJC (2013) in “Selected Topics in Nanomedicine” TMS Chang (ed), World Science Publisher/Imperial College Press
Sakai, H(2013) in “Selected Topics in Nanomedicine” Editor TMS Chang, World Science Publisher/Imperial College Press
Seetharama A. Acharya, Amy G. Tsai and Marcos Intaglietta (2013) in “Selected Topics in Nanomedicine”
Editor TMS Chang, World Science Publisher


Wong, N & TMS Chang. Artificial Cells, Blood Substitutes and Biotechnology 2007;35:481-489


Yu B, M Shahid, EM Egorina, MA Sovershaev, MJ Raher, C Lei, MX Wu, KD Bloch, WM Zapol (2010),
Anesthesiology 112:586 –594


Biotechnology 35: 518-532

Biotechnology, 41:289-292